Literature DB >> 16863917

The chemokine CXCL14 (BRAK) stimulates activated NK cell migration: implications for the downregulation of CXCL14 in malignancy.

Trevor Starnes1, Kanwaldeep Kaur Rasila, Michael J Robertson, Zacharie Brahmi, Richard Dahl, Kent Christopherson, Robert Hromas.   

Abstract

OBJECTIVE: The primary function of chemokines is the regulation of leukocyte trafficking by stimulating directional chemotaxis. The chemokine CXCL14 (BRAK) is highly expressed in all normal tissues, but is not expressed in most malignant tissues. The chemotactic activity of CXCL14 has been difficult to characterize. Recently it was reported that CXCL14 is a chemoattractant for activated monocytes and immature dendritic cells. Given that CXCL14 is downregulated upon transition to malignancy, we sought to characterize whether CXCL14 might play a role in NK cell chemotaxis.
METHODS: Human natural killer (NK) cells were isolated from buffy coats obtained from normal volunteers and were activated with lymphocyte conditioned media, IL-2, and ionomycin. Standard transwell chemotaxis assays, proliferation assays, and chromium release cell cytotoxicity assays were performed.
RESULTS: CXCL14 was found to stimulate migration of activated human NK cells in transwell chemotaxis assays by 1.4-fold. Similarly, it increased migration of an IL-2-dependent natural killer leukemia (NKL) cell line by 1.9-fold. Antisera against CXCL14 or pertussis toxin blocked this chemotactic effect. However, CXCL14 did not affect the proliferation or cytotoxic activity of normal human NK cells. CXCL14 also stimulated the chemotaxis of immature monocyte-derived dendritic cells.
CONCLUSIONS: CXCL14 may play a role in the trafficking of NK cells to sites of inflammation or malignancy. In addition, the downregulation of the expression of CXCL14 might be an important step in successful oncogenesis to prevent NK immune surveillance of the malignancy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16863917     DOI: 10.1016/j.exphem.2006.05.015

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  38 in total

1.  Chemokine CXCL14/BRAK transgenic mice suppress growth of carcinoma cell transplants. [corrected]

Authors:  Kazuhito Izukuri; Kenji Suzuki; Nobuyuki Yajima; Shigeyuki Ozawa; Shin Ito; Eiro Kubota; Ryu-Ichiro Hata
Journal:  Transgenic Res       Date:  2010-03-24       Impact factor: 2.788

2.  Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis.

Authors:  Gisele Oler; Cléber P Camacho; Flávio C Hojaij; Pedro Michaluart; Gregory J Riggins; Janete M Cerutti
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

Review 3.  The integrative roles of chemokines at the maternal-fetal interface in early pregnancy.

Authors:  Mei-Rong Du; Song-Cun Wang; Da-Jin Li
Journal:  Cell Mol Immunol       Date:  2014-08-11       Impact factor: 11.530

4.  The pathogenesis of diclofenac induced immunoallergic hepatitis in a canine model of liver injury.

Authors:  Saravanakumar Selvaraj; Jung-Hwa Oh; Reinhard Spanel; Florian Länger; Hyoung-Yun Han; Eun-Hee Lee; Seokjoo Yoon; Jürgen Borlak
Journal:  Oncotarget       Date:  2017-09-23

5.  An intronic polymorphism rs2237062 in the CXCL14 gene influences HBV-related HCC progression in Chinese population.

Authors:  Xing Gu; Hao Wang; Aihua Wang; Tonghai Dou; Peng Qi; Qiang Ji; Hui Li; Chunfang Gao
Journal:  Mol Biol Rep       Date:  2011-05-10       Impact factor: 2.316

6.  Epigenetic mechanisms of promigratory chemokine CXCL14 regulation in human prostate cancer cells.

Authors:  Eun Young Song; Michael R Shurin; Irina L Tourkova; Dmitriy W Gutkin; Galina V Shurin
Journal:  Cancer Res       Date:  2010-05-11       Impact factor: 12.701

7.  VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression.

Authors:  Joshua C Doloff; David J Waxman
Journal:  Cancer Res       Date:  2012-01-11       Impact factor: 12.701

8.  Epigenetic silencing of CXCL14 induced colorectal cancer migration and invasion.

Authors:  Baoping Cao; Yunsheng Yang; Yuanming Pan; Yan Jia; Malcolm V Brock; James G Herman; Mingzhou Guo
Journal:  Discov Med       Date:  2013-10       Impact factor: 2.970

9.  CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth.

Authors:  Martin Augsten; Christina Hägglöf; Eleonor Olsson; Claudia Stolz; Panagiotis Tsagozis; Tetyana Levchenko; Mitchell J Frederick; Ake Borg; Patrick Micke; Lars Egevad; Arne Ostman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-13       Impact factor: 11.205

10.  Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression.

Authors:  Celina G Kleer; Noga Bloushtain-Qimron; Yu-Hui Chen; Daniel Carrasco; Min Hu; Jun Yao; Stine-Kathrein Kraeft; Laura C Collins; Michael S Sabel; Pedram Argani; Rebecca Gelman; Stuart J Schnitt; Ian E Krop; Kornelia Polyak
Journal:  Clin Cancer Res       Date:  2008-09-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.